Compare · ATRC vs BDX
ATRC vs BDX
Side-by-side comparison of AtriCure Inc. (ATRC) and Becton Dickinson and Company (BDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATRC and BDX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.65B, about 30.3x ATRC ($1.37B).
- Over the past year, ATRC is down 20.8% and BDX is down 13.3% - BDX leads by 7.5 points.
- ATRC has been more active in the news (13 items in the past 4 weeks vs 10 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 14 for ATRC).
- Company
- AtriCure Inc.
- Becton Dickinson and Company
- Price
- $27.03-0.22%
- $149.41-1.19%
- Market cap
- $1.37B
- $41.65B
- 1M return
- -2.73%
- -2.40%
- 1Y return
- -20.85%
- -13.30%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- News (4w)
- 13
- 10
- Recent ratings
- 14
- 25
AtriCure Inc.
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest ATRC
- SEC Form SD filed by AtriCure Inc.
- AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
- Director Prange Karen sold $85,950 worth of shares (3,000 units at $28.65), decreasing direct ownership by 10% to 26,373 units (SEC Form 4)
- Director Prange Karen was granted 6,144 shares, increasing direct ownership by 26% to 29,373 units (SEC Form 4)
- Director Telman Deborah H was granted 6,144 shares, increasing direct ownership by 28% to 28,328 units (SEC Form 4)
- Director Yuen Maggie was granted 6,144 shares, increasing direct ownership by 54% to 17,515 units (SEC Form 4)
- Director Johnson B Kristine was granted 6,144 shares, increasing direct ownership by 12% to 55,954 units (SEC Form 4)
- Director Nachman Shlomo was granted 6,144 shares, increasing direct ownership by 33% to 24,655 units (SEC Form 4)
- Director Groves Regina E was granted 6,144 shares, increasing direct ownership by 18% to 39,859 units (SEC Form 4)
- Director Wehrwein Sven was granted 6,144 shares, increasing direct ownership by 18% to 40,518 units (SEC Form 4)
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional